PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
![Foto de PEDRO](/img/nophoto.png)
![Foto de Hospital Universitari de Bellvitge](/img/noimage_org.png)
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (15)
2024
-
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)
Journal of Neuro-Oncology
-
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
The Lancet Oncology, Vol. 25, Núm. 5, pp. 572-587
2023
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
2021
-
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 799-811
-
SEOM clinical guideline for management of adult medulloblastoma (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
-
Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 1976-1991
2017
-
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
2015
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2012
-
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
Anti-Cancer Drugs, Vol. 23, Núm. 6, pp. 659-665
-
Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors
Journal of Neuro-Oncology, Vol. 109, Núm. 1, pp. 137-142
-
Recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia
2011
-
Evidence for a link between TNFRSF11A and risk of breast cancer
Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954